• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Survey Finds Knowledge, Use of Blockchain and AI Increasing

Survey Finds Knowledge, Use of Blockchain and AI Increasing

March 22, 2021

A new survey of senior global pharma executives and other clinical trial professionals finds 89 percent have a working knowledge of blockchain, a technology that can create tamper-proof records, a key component in increasing patient participation in decentralized clinical trials. By comparison, 82 percent of respondents were familiar with blockchain when polled in 2018.

The survey found 70 percent of respondents think blockchain has the potential to be transformative in the management and sharing of patient data. Despite the enthusiasm, 30 percent of respondents say lack of access to people with relevant blockchain skills is the biggest obstacle toward expanding its use, followed by concerns over a lack of standards (19 percent) and interoperability (17 percent).

Interest in artificial intelligence (AI), which is useful in data, quality and site management, was also high, with 57 percent of respondents saying they are already using AI in computational drug repurposing. But with clinical studies generating enormous amounts of data in an increasing number of formats, 38 percent of respondents worried that algorithmic bias poses a barrier to the use of AI in drug repurposing, and an additional 42 percent said such bias could potentially be a barrier.

Pistoia Alliance, a global nonprofit founded by pharmaceutical companies, surveyed 164 executives. Respondents included digital health R&D managers, senior principal scientists, clinical trial administrators, machine learning engineers, data scientists, and informatics and data science managers.

Read the survey here: http://bit.ly/2NAzbFC.

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing